Taxonomic group: bacteria / Proteobacteria
(Phylum: Proteobacteria)
Host organism: Homo sapiens
Associated disease: bacillary dysentery (shigellosis) [ICD11:
1A02 
, ICD11:
SA56 , ICD11:
XN7HG ];
infection due to Shigella flexneri [ICD11:
XN7Y2 ]
NCBI PubMed ID: 20056180Journal NLM ID: 8406899Publisher: Elsevier
Correspondence: R. Schneerson <schneerr
exchange.nih.gov>
Institutions: Safra Children's Hospital, Sheba Medical Center, Tel Hashomer 52621, Israel
BACKGROUND: Despite its high worldwide morbidity and mortality, there is yet no licensed vaccine for shigellosis. We reported the safety and immunogenicity of Shigella O-specific polysaccharide-protein conjugates in adults and young children and efficacy of Shigella sonnei conjugate in young adults. METHODS: A double-blinded, randomized and vaccine-controlled Phase 3 evaluation of S. sonnei and Shigella flexneri 2a O-SP-rEPA conjugates, 25mug, injected IM twice, 6 weeks apart, into healthy 1-4 years old, is reported. The children were followed for 2 years by telephone every other week and stool cultures were obtained for each episode of acute diarrhea (>/=3 loose stools/day or a bloody/mucous stool). Sera were taken randomly from 10% of the participants for IgG anti-LPS and anti-carrier levels. RESULTS: Of the 2799 enrollees, 1433 received S. sonnei and 1366 S. flexneri 2a conjugates; 2699 (96.4%) completed the 2-year follow-up. Local reactions occurred in approximately 5% and approximately 4% had temperatures >/=38.0 degrees C lasting 1-2 days. There were no serious adverse events attributable to the vaccines. Of the 3295 stool cultures obtained, 125 yielded S. sonnei and 21 S. flexneri 2a. Immunogenicity and efficacy were age-related. The overall efficacy of the S. sonnei conjugate was 27.5%; 71.1% (P=0.043) in the 3-4 years old. The numbers for S. flexneri 2a were too few for meaningful analysis. Cross-protection by S. flexneri 2a for non-vaccine S. flexneri types was found, but the numbers were too few for statistical significance. There was an age-related rise of vaccine-specific IgG anti-LPS in both groups, peaking at about 10 weeks and declining thereafter, but remaining >/=4-fold higher than in the controls 2 years after the second dose. CONCLUSIONS: Shigella conjugates are safe and immunogenic in 1-4 years old. The S. sonnei conjugate elicited 71.1% efficacy in the 3-4 years old and can be predicted to be efficacious in individuals older than 3 years of age. These results urge studies with our improved conjugates.
vaccines, efficacy, shigellosis, Age-related
Structure type: polymer chemical repeating unit
Location inside paper: p. 2235
Compound class: O-polysaccharide, O-antigen, LPS
Contained glycoepitopes: IEDB_130648,IEDB_133754,IEDB_136105,IEDB_137473,IEDB_225177,IEDB_885823
Methods: serological methods, statistical analysis
Biological activity: serological data
Comments, role: published polymerization frame was shifted for conformity with other records.
Related record ID(s): 122486
NCBI Taxonomy refs (TaxIDs): 424719Reference(s) to other database(s): GTC:G17265DL, GlycomeDB:
7676
Show glycosyltransferases
There is only one chemically distinct structure:
Found 
report error